# Consensus checked against original sources: CCSVI and Liberation Therapy for Multiple Sclerosis

Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## PREMiSe adverse-direction trends are not definitive exacerbation
Consensus relied on clinical summaries rather than the requested original and described paradoxical exacerbation too decisively. The bounded original abstract reports nonsignificant between-group new-lesion and relapse trends in a 19-participant randomized phase, plus an exploratory covariance association. Its randomized target-engagement criterion was not achieved. The original body was unavailable this run: abstract-only attribution is explicit, and neither ideal mechanism ablation nor established worsening is claimed. [Original PMID24975855](https://pubmed.ncbi.nlm.nih.gov/24975855/). Access: abstract_metadata.

## Missing Canadian original and primary clinical endpoint
Consensus omitted this requested original and substituted a pooled review. Original Methods/Results were examined: 104 randomized participants, primary MSQOL54 change, secondary disability/relapse/MRI, independent assignment and blinded assessors. Both groups transiently improved; no clinical benefit separated. The planned primary-effect power was only 60%, so small or delayed effects remain bounded rather than excluded. [Original PMID30266886](https://pubmed.ncbi.nlm.nih.gov/30266886/). Access: full_text_partial.

## Clinical/MRI hierarchy and actual incomplete engagement
Consensus correctly retained 115 RRMS participants and 38/71 restored-flow treated patients. Original Methods show co-primary functional and MRI endpoints, early trial closure at 115 versus amended target300, intention-to-treat and multiplicity adjustment. Original Results include restored flow in 14/37 sham participants and favorable late nominal MRI comparisons that lost adjusted significance. These details limit a complete-blockade interpretation while preserving the negative clinical finding. [Original PMID29150995](https://pubmed.ncbi.nlm.nih.gov/29150995/). Access: full_text_partial.

## A genuine positive MRI lead from the same parent
Consensus correctly identified the expanded 130-patient analysis and positive lesion-free result, but the evidence is one Brave Dreams parent, not clinical replication. Examined original Methods/Results show added progressive patients, post hoc anatomy grading, exclusion of discordant classifications and positive MRI comparisons. The examined 2020 correction explicitly changes secondary-analysis terminology to post hoc. No numerical-effect change is stated in that correction. Prospective independent clinical validation remains the relevant gap. [Original PMID31735108](https://pubmed.ncbi.nlm.nih.gov/31735108/). Access: full_text_partial.

## Diagnostic-control originals extend the provider coverage
Consensus used initial diagnostic papers and an early CIS original, omitting the key sibling-controlled venography study. Its bounded original abstract shows greater-than-50% narrowing similarly common in MS, unaffected siblings and unrelated controls; ultrasound poorly identified catheter narrowing. The companion MRV report is grouped with this parent rather than counted as independent population replication. Anatomical narrowing alone does not establish pathological obstruction. [Original PMID24119384](https://pubmed.ncbi.nlm.nih.gov/24119384/). Access: abstract_metadata.

## Reader reproducibility is a retained positive, with its unit stated
Consensus summarized diagnostic reproducibility mainly negatively. The examined original Methods/Results retain substantial agreement between expert local and central readers, particularly for selected criteria. Shared acquired recordings differ from independently reproduced acquisition/physiology; positive reader agreement therefore survives alongside the cross-center specificity challenge. [Original PMID28721810](https://pubmed.ncbi.nlm.nih.gov/28721810/). Access: full_text_partial.

## Balloon-only objective harm without a population-rate claim
Consensus appropriately found the jugular-thrombosis case. Its bounded original abstract supports local thrombosis after balloon venoplasty without stenting despite anticoagulation, requiring surgery. This shows possible mechanical injury; it supplies neither a general incidence nor proof that every postprocedure clinical deterioration was caused by treatment. [Original PMID21803799](https://pubmed.ncbi.nlm.nih.gov/21803799/). Access: abstract_metadata.

## Potential fatal embolism is not an observed death
Consensus listed fatal pulmonary-embolus hazards among catastrophically attributed stent outcomes. The examined original case reports imaging-confirmed displacement/thrombosis and discusses a potential future fatal embolic event; no fatal pulmonary embolus was observed in this case. Device harm remains real, but speculative hazards are distinguished from observed fatalities. [Original PMID23249660](https://pubmed.ncbi.nlm.nih.gov/23249660/). Access: abstract_metadata.

## Events after treatment require attribution and correction bounds
Consensus safety wording overgeneralized causal systemic harms. This original reports serious events at variable post-treatment intervals in the same 462-person parent as the clinical report; seven jugular thromboses are mechanically plausible, while a myocardial-infarction death ten weeks later and other systemic events are not all established procedure-caused. The linked harm correction body was blocked403, so corrected numerical details remain unverified. Canadian original-body adjudication separately found its six serious events unrelated, while retaining one local jugular dissection. [Original PMID23380649](https://pubmed.ncbi.nlm.nih.gov/23380649/). Access: abstract_metadata.

## A selected timeline cannot establish a global 2026 research hiatus
Consensus claimed randomized tests ceased entirely and a complete hiatus through late 2026 based on 2019/2020 sources. The selected original wait-list trial provides a completed objective-null/subjective-mixed milestone, not proof of global absence of later trials. Our search-bounded momentum judgment names completed original programs and explicitly makes no universal current registry or regulatory-status claim. [Original PMID31445091](https://pubmed.ncbi.nlm.nih.gov/31445091/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.